MemorialCare Expands Renal Denervation Therapy to Cut Cardiovascular Deaths by 30%
Event summary
- MemorialCare launched FDA-approved Symplicity™ Renal Denervation (RDN) procedure across three hospitals on January 16, 2026.
- The therapy reduces major cardiovascular events by 20%, stroke by 27%, and heart failure by 28% in resistant hypertension patients.
- Approximately 10 million Americans have resistant hypertension, with higher prevalence among Black patients and those with chronic conditions.
- The procedure uses Medtronic's Symplicity Spyral RDN system to deliver targeted radiofrequency energy to renal arteries.
- MemorialCare operates over 200 care locations, including leading hospitals in California.
The big picture
MemorialCare's expansion of renal denervation therapy addresses a critical gap in treating resistant hypertension, a condition affecting millions of Americans. The procedure's ability to reduce cardiovascular events aligns with broader industry trends toward minimally invasive, targeted treatments. MemorialCare's system-wide implementation reflects its strategy to enhance access to advanced cardiovascular care, positioning it as a leader in innovative patient outcomes.
What we're watching
- Adoption Pace
- How quickly MemorialCare can scale the procedure across its network and compete with other healthcare systems offering similar therapies.
- Patient Outcomes
- Whether the procedure's clinical benefits translate into long-term reductions in cardiovascular mortality and morbidity.
- Regulatory Dynamics
- The impact of FDA approvals and guidelines on the broader adoption of renal denervation therapies.
Related topics